



14 August 2019

RESPIRI PROGRESSES INDIAN MARKET ENTRY

Respiri Limited (RSH:ASX) (“Respiri” or the “Company”) is pleased to update shareholders on the recent visit by key personnel to the Indian capital, New Delhi to build the Company’s connection with healthcare leaders, government officials and influencers, introduced by JV partner, MedAchievers.

MedParliament | Invitation Only Healthcare Leaders Summit | 29 - 31 July 2019

Staged by Dr Harsha Vardhan and MedAchievers, the MedParliament Healthcare Leaders Summit provided an unparalleled platform for Respiri to showcase its technology, business objectives and commitment to its India strategy to key hospital owners, head pulmonologists, healthcare decision makers and government officials, including the Hon. Mr Ashwini Kumar Choubey, Minister of State for Health and Family Welfare. The Company was represented in two panel discussions, alongside Australia’s Deputy High Commissioner, Mr Rod Hilton, and by Michael Clarke, Respiri brand ambassador, in a widely reported interview describing his commitment to the Company and its mission to help millions of people living with asthma. Highlights of the summit will be broadcast by media partners, CNBC and Forbes in coming days. These valuable media assets will be developed for our communications and promotion in the local Australian market.

Private Meetings with Decision Makers | Phase 1 Hospital Pilots

Key to the success of the three-day summit for Respiri were the private meetings with a number of hospital owners to discuss Phase 1 pilots in Tier 1 hospitals in major Indian cities. The objective of the pilots is to evaluate and plan the implementation of wheezo™ in their institutions. Completion of Phase 1 is expected to lead to significant orders in conjunction with the CE mark and established manufacturing. Respiri is now finalising those discussions and looks forward to providing shareholders with further details. In addition to the private meetings with hospital leadership, Dr Vardhan arranged for the Company to demonstrate the product to the Uttar Pradesh Health Minister, the Hon. Mr Siddharth Nath Singh in a private meeting. Uttar Pradesh is the most populous state in India with over 200 million inhabitants, and as such must provide for millions suffering with respiratory disease needing effective monitoring and management. There is potential government support for manufacturing in the state’s Special Economic Zone (SEZ).

Conference Call | 11am Today

Respiri invites you to join a conference call to hear the latest news directly from Mario Gattino and Professor Bruce Thompson. **Today, 14 August 2019 | 11.00am AEDT**

Telephone: 1800 123 296

Conference ID 9570218

Should you have any questions that arise during the presentation, we ask that you email these live to admin@respiri.co and the speakers will address as many of these as possible at the end of the presentation.

--END--

Contact:

Mario Gattino

CEO

+61 9653 9160

About Respiro Limited

Respiro's mission is to help improve quality of life for millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. The Company offers sensors, mobile apps and analytics to support respiratory health management. Its world first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. Respiro's innovative platform provides personalised feedback and education based on the user's data and enables the sharing of that data with caregivers and health care providers. Respiro Limited's operations are based in Melbourne, Australia.

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward looking statements are not historical facts but rather are based on Respiro's current expectations, estimates and projections about the industry in which Respiro operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Respiro, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. Respiro cautions shareholders and prospective shareholders not to place undue reliance on these forward looking statements, which reflect the view of Respiro only as of the date of this release. The forward looking statements made in this announcement relate only to events as of the date on which the statements are made. Respiro will not undertake any obligation to release publicly any revisions or updates to these forward looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.